CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology (CST), where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Hallmarks of Cancer: Inducing Angiogenesis Energetics

Read More
All Posts

Cancer cells stimulate the growth of blood vessels to supply nutrients to tumors. Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. This plays an important role in tumor growth.

18-CEL-47663-Blog-Hallmarks-Cancer-3-Inducing-Angiogenesis

Benign tumors can exist in a dormant state, which can be driven by inadequate access to sufficient blood supply. However, the "angiogenic switch" occurs when angiogenesis is activated in a dormant tumor and growth factors are secreted to induce sprouting and chemotaxis of endothelial cells toward the tumor mass.

Within the hypoxic environment of the tumor mass, hypoxia inducible factor-1 (HIF-1) is stabilized and activates the expression of multiple genes contributing to the angiogenic process, including vascular endothelial growth factor (VEGF) and fibroblast growth factor (bFGF), or platelet-derived growth factor (PDGF).

Click the angiogenesis pathway link to learn more about the related proteins implicated in this Hallmark of Cancer:

 - Angiogenesis Pathways

Check out the complete guide to the Hallmarks of Cancer Research targets. Download the eBook Now.

The Hallmarks of Cancer were identified by Doctors Robert Weinberg and Douglas Hanahan and were originally published in Cell1. The authors propose the idea that the complexity of cancer can be broken down into smaller subsets of underlying principles. The information here pertains to one such subset. Other entries in this series explore the other known Hallmarks.

Read the additional blog posts in the Hallmarks of Cancer series to learn more:

  1.  Hanahan D, Weinberg RA (January 2000). "The Hallmarks of Cancer". Cell. 100 (1): 57–70. doi:10.1016/S0092-8674(00)81683-9
  2. Hanahan D, Weinberg RA (March 2011). "Hallmarks of Cancer: the next generation". Cell. 144 (5):646-74. doi: 10.1016/j.cell.2011.02.013.
Chris Sumner
Chris Sumner
Chris Sumner was the Editor-in-Chief of Lab Expectations. When he's not reading/writing about curing disease, he's hiking in the woods, playing guitar, or searching for the world's best lobster roll.

Recent Posts

Cell Preparation Tips for Accurate Flow Cytometry Data

Generating accurate flow cytometry data requires more than just specific and sensitive antibodies validat...
Andrea Tu, PhD Nov 20, 2024

500 Antibodies & Counting: Accelerating Discovery with CST Antibodies Validated for Simple Western Technology

Since 2022, Cell Signaling Technology (CST) and Bio-Techne have been working together to bring best-in-cl...
Chris LaBreck, PhD Oct 23, 2024

Menin-KMT2A Inhibitors: A Promising Approach to Acute Myeloid Leukemia (AML) Treatment

Accounting for about 80% of adult acute leukemias, acute myeloid leukemia (AML) is an aggressive form of ...
Homa Rahnamoun, PhD Oct 16, 2024